Literature DB >> 29061246

Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease.

Michael J Bradshaw1, Tracey A Cho2, Felicia C Chow3.   

Abstract

Patients on immunosuppressive therapy for rheumatic diseases are at increased risk of infection. Although infections of the central nervous system (CNS) are less common compared with other sites, patients on broadly immunosuppressive and biologic immunomodulatory agents may be susceptible to more severe, disseminated forms of infection, including of the CNS. Certain key principles regarding infection risk apply across immunosuppressive therapies, including increased risk with higher doses and longer duration of therapy and with combination therapy. Providers should be aware of the CNS infection risk related to immunosuppressant use to help guide best practices for screening and prophylaxis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Central nervous system infection; Immunomodulatory therapy; Immunosuppression; Rheumatic disease

Mesh:

Substances:

Year:  2017        PMID: 29061246      PMCID: PMC5679400          DOI: 10.1016/j.rdc.2017.06.009

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  94 in total

Review 1.  Cryptococcal meningitis in a patient treated with infliximab.

Authors:  Patricia Muñoz; Maddalena Giannella; Maricela Valerio; Teresa Soria; Fernando Díaz; Javier Lopez Longo; Emilio Bouza
Journal:  Diagn Microbiol Infect Dis       Date:  2007-01-19       Impact factor: 2.803

Review 2.  Leukoencephalopathy induced by low-dose methotrexate in a patient with rheumatoid arthritis.

Authors:  Masayuki Matsuda; Dai Kishida; Tomomi Kinoshita; Akiyo Hineno; Yasuhiro Shimojima; Kazuhiro Fukushima; Shu-ichi Ikeda
Journal:  Intern Med       Date:  2011-10-01       Impact factor: 1.271

3.  Initial functional status predicts infections during steroid therapy for renal diseases.

Authors:  Y Sakuma; T Katoh; K Owada; H Suzuki; K Sakurai; M Eiro; K Asahi; T Watanabe
Journal:  Clin Nephrol       Date:  2005-02       Impact factor: 0.975

4.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.

Authors:  David B Clifford; Beau Ances; Craig Costello; Shari Rosen-Schmidt; Magnus Andersson; Deborah Parks; Arie Perry; Raju Yerra; Robert Schmidt; Enrique Alvarez; Kenneth L Tyler
Journal:  Arch Neurol       Date:  2011-05-09

5.  Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2004-08-06       Impact factor: 17.586

6.  Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor.

Authors:  F Paliogianni; S S Ahuja; J P Balow; J E Balow; D T Boumpas
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

7.  Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts.

Authors:  A Tobler; R Meier; M Seitz; B Dewald; M Baggiolini; M F Fey
Journal:  Blood       Date:  1992-01-01       Impact factor: 22.113

8.  Leukoencephalopathy due to oral methotrexate.

Authors:  I González-Suárez; M J Aguilar-Amat; M Trigueros; A M Borobia; A Cruz; J Arpa
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

9.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

10.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08
View more
  1 in total

Review 1.  CNS Infections in Immunoincompetent Patients : Neuroradiological and Clinical Features.

Authors:  Stefan Weidauer; Marlies Wagner; Simon Jonas Enkirch; Elke Hattingen
Journal:  Clin Neuroradiol       Date:  2019-09-19       Impact factor: 3.649

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.